Pricing issues in China keep investors at bay: Report

Furthermore, the report also pointed out that during June 2013, Germany-based Boehringer Ingelheim signed an agreement with Zhangjiang Biotech and Pharmaceutical Base Development company to construct a biopharmaceutical facility that will meet good manufacturing practice (cGMP) standards. Boehringer Ingelheim plans to invest over $46.4 million. With the establishment of the new facility, Boehringer Ingelheim will have two manufacturing facilities and two R&D centers in China.